This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the glioblastoma multiforme (brain cancer) market not available elsewhere. This reports gives an overview of the current and future brain cancer clinical development market, the activities of the key market players, and outlines trial and commercial regulatory environments.

1. EW
PR
EV
I
Brain Cancer
(Glioblastoma Multiforme):
Disease and Pipeline
Analysis
Info@ISRreports.com
©2014 Industry Standard Research
www.ISRreports.com

2. act with confidence
Report Overview
This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view
of the glioblastoma multiforme (brain cancer) market not available elsewhere. This reports gives an overview
of the current and future brain cancer clinical development market, the activities of the key market players, and
outlines trial and commercial regulatory environments.
57
Major Sections:
1. Disease Overview
Companies Included
12
2. Commercial Rationale
59
4. Clinical Development Pipeline
3. Environmental Analysis
Countries Analyzed
5. The Clinical Trial Environment
Pages
What you will learn in this report:
•
Global and country-specific incidence rates for glioblastoma multiforme
•
Active development pipeline, including promising new therapies currently in Early and Late
Phases of development
•
Country-specific analysis of clinical trial environments for new glioblastoma multiforme
therapies
How you can use this report:
•
Identify and enhance commercial and development opportunities with an in-depth and
current analysis of the global glioblastoma multiforme market
•
Understand how products currently in development could impact this market and how large
and small pharma is involved
•
Assess the competition with an analysis and summary of companies playing in this space
Valuable for:
•
Brand Managers
•
Portfolio Managers
•
Research & Development
•
Managed Markets
NEXT: List of Companies Included
www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
2

3. act with confidence
Companies Included:
Descriptions of product names, mechanism of actions (MOA), and highest development phase for the
following companies:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
AbbVie
Actelion Pharma
Activartis
Aduro Biotech
Advantagene
Agenus
Amgen
Angiochem
Antisense Pharma
Apogenix
Archer Biosciences
Arno Therapeutics
Ascenta Therapeutics
AstraZeneca (MedImmune)
BristolMeyersSquibb
Cell Therapeutics
Celldex Therapeutics
CytoVac A/S
DelMar Pharma
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Dendreon
Diffusion Pharma
DNAtrix Inc
Eisai
Eli Lilly (Imclone)
EMD Serono
EnGenIC
Erimos Pharma
Genentech
GW Pharma
Immatics Biotechnologies
ImmunoCellular Therapeutics
Innocell Corp
Lentigen
Merck (Schering-Plough)
Merck KGaA
Northwest Biotherapeutics
Novartis
NovaRx
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Oncolytics Biotech
Oncothyreon
Oncovir Inc.
Peregrine Pharma
Plexxikon
Roche
Sangamo Biosciences
Sanofi (Exelixis)
Sanofi Aventis
StemLine Therapeutics
Tau Therapeutics
Thallion Pharma
Threshold Pharma
To-BBB technologies BV
Tocagen
TVAX Biomedical
Valycyte
VBL Therapeutics
Visualase Inc.
•
•
•
•
India
Italy
Japan
Russia
•
•
•
•
South Korea
Spain
United Kingdom
United States
Regions Analyzed:
•
•
•
•
Brazil
China
France
Germany
NEXT: Table of Contents and Sample Pages
www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
3

4. act with confidence
Table of Contents
For table of contents and additional sample pages, download the full preview
from our website:
http://www.isrreports.com/product/brain-cancer-glioblastoma-multiformedisease-pipeline-analysis/
www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
4

5. act with confidence
Sample Page
Introduction
act with confidence
disease & Development
BRAIN CANCER
Glioblastoma Multiforme (GBM)
one of the
deadliest
cancer types.
5y
e
r
a
v
Sur ival
e
at
R
r
tumo s
NS
Rapid tumor growth, highly resistant tumors, and a
lack of effective therapies contribute to making this
onstitute
as c
a
m
imately 30
rox
%
pp
Gl
io
GBM is the most common and most aggressive form of primary malignant brain tumor.
Breast Cancer: 89%
Colorectal: 64%
Glioblastoma: 4.8%
Lung: 15%
Prostate: 99%
rain an
dC
all b
of
240,000 people
are diagnosed with GBM
globally each year. That’s
equivalent to the population
of Durham, NC.
GBM is classified as an
that’s
orphan disease.
This is defined as a disease
that affects fewer than
200,000 people (in the U.S.).
2-3 cases
per
100,000
adults
Without treatment,
the mean life
expectancy is
approximately
4.5 months.
With standard of
care treatment
average life
expectancy rises to
approximately
15 months.
Potential therapies can be
eligible for Orphan
Drug Designation, which
allows the developing
company to receive tax
breaks and market
exclusivity upon approval of
the therapy.
76 GBM clinical trials
were started in 2013
GBM is slightly
more common in
males
and slightly more
common in
Caucasians (in US).
50 potential
new therapies
in active development, positive
results in early stage trials.
These new therapies include:
• Immunotherapeutic Vaccines
• Anti-Angiogenesis
• Gene Therapy
• Cell Signaling Pathway Inhibitors
• Cytotoxics
58 PHARMA & biotech
companies have sponsored GBM
trials since 2010.
Sources: ISR Reports, brain�mgh�harvard�edu, cancer�org, http://visual�ly/brain-cancer-infographic, www�mdanderson�org, seer�cancer�gov
www.ISRreports.com ©2014 | Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
5
www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com).
5

6. act with confidence
Sample Page
For table of contents and additional sample pages, download the full preview
from our website:
http://www.isrreports.com/product/brain-cancer-glioblastoma-multiformedisease-pipeline-analysis/
www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
6

7. act with confidence
Ordering Information
For pricing and orderng information, please visit our website:
http://www.isrreports.com/product/brain-cancer-glioblastoma-multiformedisease-pipeline-analysis/
Save on this,
or any ISR
report, by
registering a
free account
Register now
• Receive a $250 instant credit towards any ISR report
• Earn 10% credit towards all future purchases
• Receive advanced notifications on ISR’s latest reports and free resources
About Industry Standard Research
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.
For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.
ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
7

8. The ISR Difference
act with confidence
Custom-quality syndicated market research
www.ISRreports.com
ISR's Reports
vs.
The Common
Syndicated Report
How confident are you?
Research methods
vs.
vs.
Mostly primary
research;
always appropriate
for the topic
One size fits all;
usually publically
available data
Data Collection
ISR's proprietary data collection
tools and channels support fast,
high quality data collection
vs.
Struggle to recruit the right
targets and enough of them
Respondents
vs.
Sophisticated screening
ensures genuine
decision-makers
Undisclosed
methodologies and
respondent demographics
Sample Sizes
vs.
Robust sample sizes that
instill confidence
Often insufficient industry
representation that leaves you
defending results
Analysts
Decades of experience
means more insights that are
immediately usable
vs.
vs.
Junior analysts capable of
reporting numbers
www.ISRreports.com ©2014 | Preview of:©2013Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis
www.ISRreports.com Brain | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 8